LEADER 03409nam 2200589Ia 450 001 9910143285503321 005 20170815110925.0 010 $a1-280-74319-0 010 $a9786610743193 010 $a0-470-79480-1 010 $a0-470-99474-6 010 $a1-4051-7253-3 035 $a(CKB)1000000000342165 035 $a(EBL)284207 035 $a(OCoLC)85822919 035 $a(SSID)ssj0000169741 035 $a(PQKBManifestationID)11153740 035 $a(PQKBTitleCode)TC0000169741 035 $a(PQKBWorkID)10203680 035 $a(PQKB)11605365 035 $a(MiAaPQ)EBC284207 035 $a(EXLCZ)991000000000342165 100 $a20060109d2006 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aHeart failure$b[electronic resource] $epharmacologic management /$fedited by Arthur M. Feldman 210 $aOxford $cBlackwell Futura$d2006 215 $a1 online resource (306 p.) 300 $aDescription based upon print version of record. 311 $a1-4051-0361-2 320 $aIncludes bibliographical references. 327 $aHeart Failure: Pharmacologic Management; Contents; Contributors; Introduction; 1 Diuretics in congestive heart failure; 2 Use of digoxin in the treatment of heart failure; 3 Renin-angiotensin system and angiotensin converting enzyme inhibitors in chronic heart failure; 4 Angiotensin receptor blockers in the treatment of heart failure; 5 Beta blockers; 6 Aldosterone antagonism in the pharmacological management of chronic heart failure; 7 Inotropic therapy in clinical practice; 8 Antiarrhythmic therapy in heart failure 327 $a9 Treating the hypercoagulable state of heart failure: modifying the risk of arterial and venous thromboembolism10 Vasodilator and nitrates; 11 Natriuretic peptides for the treatment of heart failure; 12 Immune modulatory therapies in heart failure: using myocarditis to gain mechanistic insights; 13 The role of vasopressin and vasopressin antagonists in heart failure; 14 Role of erythropoietin in the correction of anemia in patients with heart failure; 15 Endothelin antagonism in cardiovascular disease; 16 Pharmacogenetics; 17 Management of diastolic dysfunction 327 $a18 Multidrug pharmacy for treatment of heart failure: an algorithm for the clinicianIndex 330 $aNow there is an up-to-date guide for optimizing pharmacologic therapy in treating patients with heart failure. Reflecting current practice at leading medical centers, Heart Failure: Pharmacologic Management provides both the biologic and pathologic underpinnings of each pharmacologic agent in current use. It also supplies detailed discussions of the clinical investigations that support current understanding of the risks and benefits associated with the use of these drugs. Thorough references make the book useful to the novice as well as the experienced clinician. Initial cha 606 $aCongestive heart failure$xChemotherapy 606 $aHeart 608 $aElectronic books. 615 0$aCongestive heart failure$xChemotherapy. 615 0$aHeart. 676 $a616.129061 701 $aFeldman$b Arthur M$g(Arthur Michael),$f1949-$0856065 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910143285503321 996 $aHeart failure$91911280 997 $aUNINA LEADER 01276nam 2200409 450 001 9910812144103321 005 20230126222417.0 010 $a1-78973-985-3 035 $a(CKB)4100000010858294 035 $a(MiAaPQ)EBC6148266 035 $a(EXLCZ)994100000010858294 100 $a20200629d2020 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aEntrepreneurship for deprived communities $edeveloping opportunities, capabilities and enterprise culture /$fNikolai Mouraviev and Alex Avramenko 210 1$aBingley, England :$cEmerald Publishing,$d[2020] 210 4$dİ2020 215 $a1 online resource (xiii, 203 pages) $cillustrations 225 1 $aEmerald points 300 $aIncludes index. 311 $a1-78973-988-8 410 0$aEmerald points. 606 $aEntrepreneurship$xSocial aspects 615 0$aEntrepreneurship$xSocial aspects. 676 $a306.34 700 $aMouraviev$b Nikolai$0933072 702 $aAvramenko$b Alex 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910812144103321 996 $aEntrepreneurship for deprived communities$94070028 997 $aUNINA